Looking at the annual revenues chart may be disconcerting, but reality is not as bad as it looks. At the beginning of 2013, Abbott spun off AbbVie (NYSE:ABBV) to shareholders (I was fortunate to be one at the time). My data source picked up the restated numbers reported by ABT for 2011 and 2012 as though the companies had already split. In reality, the revenue for ABT did not drop until 2013 post-split. But no matter how one looks at the result, for those holding ABT shares, only revenues have been relatively flat since the spin-off. The compound annual rate of growth since then has been 2.3 percent.

READ FULL ARTICLE HERE